 ROCKVILLE, Md., Oct. 18, 2021 GLOBE NEWSWIRE -- OpGen, Inc. Nasdaq: OPGN, OpGen or the Company, a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock and warrants to purchase up to an aggregate of 7,500,000 shares of common stock for gross proceeds of 15 million. The shares of preferred stock have a stated value of 100 per share and are convertible into an aggregate of 7,500,000 shares of common stock at a conversion price of 2.00 per share at any time after the Company has received shareholder approval to increase the number of authorized shares of common stock of the Company. The warrants have an exercise price of 2.05 per share, will become exercisable on the later of the date of shareholder approval and six months following the date of issuance, and will expire five years following the initial exercise date. 